Back to Journals » OncoTargets and Therapy » Volume 13
RETRACTED ARTICLE: Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma
Authors Yang P, Zhang L, Wang T, Liu Q, Wang J, Wang Y, Tu Z, Lin F
Received 30 April 2020
Accepted for publication 13 July 2020
Published 12 August 2020 Volume 2020:13 Pages 8055—8067
DOI https://doi.org/10.2147/OTT.S259428
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sanjay Singh
This paper has been retracted.
Yang P, Zhang L, Wang T, et al. Onco Targets Ther. 2020;13:8055—8067. https://doi.org/10.2147/ott.s259428
We, the Editors and Publisher of the journal OncoTargets and Therapy, have retracted the published article.
After publication, concerns have been raised by a third party in 2026 about the integrity of the data in Figures 6 and 7 of the article.
Further investigation conducted by the Journal and Publisher confirmed unusual similarities present within the image panels representative of different treatment conditions in Figures 6, and 7.
When approached for an explanation, the authors did not respond to the queries raised by the Journal and Publisher.
As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed.
We have been informed in our decision-making by our editorial policies and the COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.
© 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.